{"id":"covid-19-convalescent-hyperimmune-plasma","safety":{"commonSideEffects":[{"rate":"null","effect":"Thrombosis"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This treatment involves infusing plasma from individuals who have recovered from COVID-19, which contains antibodies that can help neutralize the virus. These antibodies can provide immediate protection to patients who are severely ill or at high risk of developing severe disease.","oneSentence":"COVID-19 convalescent hyperimmune plasma works by transferring antibodies from recovered COVID-19 patients to help the body fight the virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:15.488Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of severe COVID-19"}]},"trialDetails":[{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT05157165","phase":"","title":"Convalescent Plasma in Hospitalized COVID-19 Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Azienda Socio Sanitaria Territoriale di Mantova","startDate":"","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04891172","phase":"PHASE2, PHASE3","title":"Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2021-08-01","conditions":"Covid19","enrollment":310},{"nctId":"NCT04366245","phase":"PHASE1, PHASE2","title":"Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","status":"COMPLETED","sponsor":"Andalusian Network for Design and Translation of Advanced Therapies","startDate":"2020-04-23","conditions":"SARS-CoV 2","enrollment":72},{"nctId":"NCT04721236","phase":"NA","title":"Early Use of Hyperimmune Plasma in COVID-19","status":"UNKNOWN","sponsor":"Catherine Klersy","startDate":"2020-11-19","conditions":"Covid19","enrollment":260},{"nctId":"NCT04405310","phase":"PHASE2","title":"Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial","status":"COMPLETED","sponsor":"Grupo Mexicano para el Estudio de la Medicina Intensiva","startDate":"2020-05-20","conditions":"SARS Pneumonia","enrollment":42},{"nctId":"NCT04622826","phase":"PHASE2","title":"plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients","status":"UNKNOWN","sponsor":"Azienda USL Toscana Nord Ovest","startDate":"2020-05-15","conditions":"Covid-19 Pneumonia","enrollment":50},{"nctId":"NCT04392414","phase":"PHASE2","title":"Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease","status":"COMPLETED","sponsor":"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","startDate":"2020-05-01","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04385043","phase":"PHASE2, PHASE3","title":"Hyperimmune Plasma in Patients With COVID-19 Severe Infection","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-05-01","conditions":"COVID-19","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"COVID-19 convalescent hyperimmune plasma","genericName":"COVID-19 convalescent hyperimmune plasma","companyName":"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia","companyId":"federal-research-clinical-center-of-federal-medical-biological-agency-russia","modality":"Biologic","firstApprovalDate":"","aiSummary":"COVID-19 convalescent hyperimmune plasma works by transferring antibodies from recovered COVID-19 patients to help the body fight the virus. Used for Treatment of severe COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}